Company intelligence / Profile preview

Gamida Cell

Ownership: Public · GMDA
Employees: ~100
Development stage: Commercial

Overview

Gamida Cell’s lead product, omidubicel (Omisirge), received FDA approval in April 2023 as an allogeneic umbilical cord blood-derived stem cell therapy to reduce infection risk in patients with blood cancer undergoing bone marrow transplant. Clinical studies showed faster neutrophil engraftment and reduced infections compared to standard cord blood transplants. The company also has a pipeline of NAM-enabled natural killer cell therapies at various stages of development but deprioritized some preclinical work due to financial constraints.

Therapeutic areas: HematologyOncology
Modalities: Allogeneic cell therapy (umbilical cord blood-derived stem cells)Natural killer (NK) cell therapies
Industry: Biotech

Drug pipeline

12 assets

omidubicel

Approved

11 more assets in the full pipeline.

Request access →

Partnerships

Collaboration with Dana-Farber Cancer Institute on GDA–601 program targeting multiple myeloma; seeking additional strategic partners or acquirers as of early/mid–2024.

Financials

Market cap: $4.3M
Total revenue: $890K
Enterprise value: $57.6M

Beyond the preview

Go deeper on Gamida Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamida Cell.

Explore the full profile